Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ADCT | US
0.25
8.22%
Healthcare
Biotechnology
30/06/2024
04/10/2024
3.29
3.10
3.36
3.09
ADC Therapeutics SA a commercial-stage biotechnology company develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7 a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD"dimer toxin as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition it develops ADCT-602 which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212 a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA) including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S Bergenbio AS Synaffix B.V. Mitsubishi Tanabe Pharma Corporation Overland Pharmaceuticals and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges Switzerland."
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
67.3%1 month
56.2%3 months
80.7%6 months
87.1%-
-
2.58
-0.94
0.33
-1.43
1.71
-
-137.47M
318.10M
318.10M
-
-166.81
-
-9.70
-705.53
9.19
4.65
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.49
Range1M
0.78
Range3M
1.60
Rel. volume
0.75
Price X volume
865.01K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
INZY | INZY | Biotechnology | 5.17 | 346.90M | 2.78% | n/a | 49.47% |
Nautilus Biotechnology Inc. | NAUT | Biotechnology | 2.71 | 339.86M | -0.73% | n/a | 13.86% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 6.49 | 337.66M | 2.69% | n/a | 0.38% |
AC Immune SA | ACIU | Biotechnology | 3.38 | 334.42M | -2.87% | n/a | 0.00% |
XOMA Corporation | XOMA | Biotechnology | 27.64 | 323.51M | 0.95% | n/a | 121.93% |
MeiraGTx Holdings plc | MGTX | Biotechnology | 4.15 | 320.31M | -1.89% | n/a | 109.40% |
Aldeyra Therapeutics Inc | ALDX | Biotechnology | 5.34 | 317.31M | 0.75% | n/a | 15.90% |
Cerus Corporation | CERS | Biotechnology | 1.7 | 315.00M | 0.59% | n/a | 199.34% |
Immutep Limited | IMMP | Biotechnology | 2.05 | 314.34M | -3.07% | n/a | 0.84% |
Monte Rosa Therapeutics Inc | GLUE | Biotechnology | 5.09 | 312.39M | -5.57% | n/a | 19.74% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.43 | 0.76 | Cheaper |
Ent. to Revenue | 1.71 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.58 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 80.67 | 74.67 | Par |
Debt to Equity | -0.94 | -1.82 | Expensive |
Debt to Assets | 0.33 | 0.26 | Expensive |
Market Cap | 318.10M | 3.73B | Emerging |